Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for neurological and endocrine disorders. The company's research and development efforts are focused on discovering novel drugs that target the underlying causes of these disorders. With a diverse pipeline of product candidates, including treatments for Parkinson's disease, schizophrenia, and endometriosis, Neurocrine Biosciences is dedicated to improving the lives of patients with neurological and endocrine disorders. Their lead product, Ingrezza, is the first and only FDA-approved treatment for adults with tardive dyskinesia, a movement disorder caused by long-term use of certain medications. Neurocrine Biosciences is committed to addressing unmet medical needs and developing innovative therapies to improve patient outcomes.